Personalized medicine: when the common becomes the rare.
作者信息
O'Connor Daniel J
机构信息
The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom.
出版信息
Front Med (Lausanne). 2024 Dec 18;11:1523594. doi: 10.3389/fmed.2024.1523594. eCollection 2024.
Abstract
摘要
相似文献
1
Personalized medicine: when the common becomes the rare.个性化医疗：当常见变为罕见时。
Front Med (Lausanne). 2024 Dec 18;11:1523594. doi: 10.3389/fmed.2024.1523594. eCollection 2024.
2
N-of-1 Trials in Pediatric Oncology: From a Population-Based Approach to Personalized Medicine-A Review.儿科肿瘤学中的单病例试验：从基于人群的方法到个性化医疗——综述
Cancers (Basel). 2021 Oct 29;13(21):5428. doi: 10.3390/cancers13215428.
3
Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics.个性化医疗与伴随诊断的当前趋势：来自药物信息协会（DIA）个性化医疗与伴随诊断会议的总结
Ther Innov Regul Sci. 2015 Jul;49(4):530-543. doi: 10.1177/2168479015570330.
4
Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach.中医个性化医学的未来展望：系统生物学方法。
Complement Ther Med. 2012 Feb-Apr;20(1-2):93-9. doi: 10.1016/j.ctim.2011.10.007. Epub 2011 Nov 30.
5
Conference Scene: Is personalized medicine ready for prime time?会议现场：个性化医疗准备好迎来黄金时代了吗？
Per Med. 2012 Jul;9(5):475-478. doi: 10.2217/pme.12.57.
6
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics.药物基因组学与罕见病：优化药物研发与个性化治疗
Pharmacogenomics. 2025 Feb-Mar;26(3-4):121-128. doi: 10.1080/14622416.2025.2490465. Epub 2025 Apr 7.
7
[Clinical and health economic challenges of personalized medicine].[个性化医疗的临床与卫生经济挑战]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 May;55(5):710-4. doi: 10.1007/s00103-012-1479-2.
8
Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.今日个体化心血管医学：美国食品药品监督管理局/药品评价和研究中心视角
Circulation. 2015 Oct 13;132(15):1425-32. doi: 10.1161/CIRCULATIONAHA.114.009761.
9
E-Science technologies in a workflow for personalized medicine using cancer screening as a case study.以癌症筛查为例的个性化医疗工作流程中的电子科学技术。
J Am Med Inform Assoc. 2017 Sep 1;24(5):950-957. doi: 10.1093/jamia/ocx038.
10
Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?创新的支付方参与策略：这种融合会在个性化医疗中带来更好的价值创造吗？
EPMA J. 2017 Feb 13;8(1):5-15. doi: 10.1007/s13167-017-0078-6. eCollection 2017 Dec.
本文引用的文献
1
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.ESMO 肿瘤不可知分类器和筛查器（ETAC-S）：一种用于评估基于分子靶向治疗的肿瘤不可知性和指导药物开发的工具。
Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25.
2
Empowering effective biomarker-driven precision oncology: A call to action.赋能有效的基于生物标志物的精准肿瘤学：行动呼吁。
Eur J Cancer. 2024 Sep;209:114225. doi: 10.1016/j.ejca.2024.114225. Epub 2024 Jul 15.
3
Defining rare conditions in the era of personalized medicine.在个性化医疗时代定义罕见病。
Nat Rev Drug Discov. 2023 Nov;22(11):857-858. doi: 10.1038/d41573-023-00145-2.
4
A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.瑞士药品管理局、欧洲药品管理局和美国食品药品监督管理局对肿瘤药物和其他非肿瘤药物的监管决策模式的十年比较。
Clin Transl Sci. 2023 Sep;16(9):1569-1581. doi: 10.1111/cts.13567. Epub 2023 Jul 5.
5
New clinical trial designs in the era of precision medicine.精准医学时代的新型临床试验设计。
Mol Oncol. 2019 Mar;13(3):549-557. doi: 10.1002/1878-0261.12465. Epub 2019 Feb 22.
6
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.欧盟监管机构与卫生技术评估机构的观点有多一致？监管-卫生技术评估并行科学建议的比较分析。
Br J Clin Pharmacol. 2016 Oct;82(4):965-73. doi: 10.1111/bcp.13023. Epub 2016 Jul 1.
Zotero 插件